Larisa Girshova

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Adès, Larisa Girshova, Vadim Doronin et al. · Blood Advances · 2022 · 112 citations · Full text

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial

Marina Konopleva, Christoph Röllig, Jamie Cavenagh et al. · Blood Advances · 2022 · 68 citations · Full text

Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy ^*

Toshihiro Miyamoto, David Sanford, Ciprian Tomuleasa et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2022 · 25 citations

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report

Aleksina Shatilova, Larisa Girshova, Daniil Zaytsev et al. · BMC Women s Health · 2021 · 16 citations · Full text

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim Doronin et al. · Blood · 2021 · 11 citations